论文部分内容阅读
目的研究c-jun氨基末端激酶(JNK)的磷酸化活性形式p-JNK在乳腺癌组织中的表达及其在乳腺癌耐药中的作用。方法通过免疫组化法研究60例乳腺癌和20例乳腺癌旁组织切片中p-JNK的表达,并探讨p-JNK与P糖蛋白(p-gp)、多药耐药相关蛋白1(MRP1)和肺耐药相关蛋白(LRP)表达的相关性。结果p-JNK在乳腺癌中的阳性表达率为70.0%,高于癌旁组织的35.0%,两者差异有统计学意义(P<0.01)。P-gp,MRPP1,LRP在乳腺癌组织中的阳性表达率分别为36.7%,81.7%,83.3%,均高于癌旁组织。LRP与腋窝淋巴结转移有关;该指标分组间差异有显著性(P<0.05)。p-JNK表达与P-gp和MRP1表达呈正相关(r=0.272,0.348;P<0.05),与LRP表达无关(P>0.05)。结论p-JNK高表达在乳腺癌发生中发挥了作用,与P-gp和MRP1的协同表达提示p-JNK与乳腺癌多药耐药有关。
Objective To study the expression of p-JNK, a phosphorylated c-Jun N-terminal kinase (JNK), in breast cancer and its role in drug resistance in breast cancer. Methods The expression of p-JNK in 60 cases of breast cancer and 20 cases of paracancerous tissues of breast cancer was studied by immunohistochemistry. The expressions of p-JNK, p-gp, MRP1 ) And lung resistance-related protein (LRP) expression. Results The positive rate of p-JNK in breast cancer was 70.0%, which was higher than that in adjacent tissues (35.0%). The difference was statistically significant (P <0.01). The positive rates of P-gp, MRPP1 and LRP in breast cancer tissues were 36.7%, 81.7% and 83.3%, respectively, which were higher than those in paracancerous tissues. LRP was related to axillary lymph node metastasis. There was significant difference between the two groups (P <0.05). The expression of p-JNK was positively correlated with the expression of P-gp and MRP1 (r = 0.272,0.348; P <0.05), but not with the expression of LRP (P> 0.05). Conclusion The high expression of p-JNK plays a role in the development of breast cancer. The co-expression of p-gp and MRP1 suggests that p-JNK is associated with multidrug resistance in breast cancer.